We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · July 14, 2021

Clinical Outcomes After Anti-TNF Discontinuation in >1000 IBD Patients

Alimentary Pharmacology & Therapeutics

 

Additional Info

Alimentary Pharmacology & Therapeutics
Clinical Outcome After Anti-Tumour Necrosis Factor Therapy Discontinuation in 1000 Patients With Inflammatory Bowel Disease: The EVODIS Long-Term Study
Aliment. Pharmacol. Ther. 2021 Jun 01;53(12)1277-1288, MJ Casanova, M Chaparro, Ó Nantes, JM Benítez, M Rojas-Feria, J Castro-Poceiro, JM Huguet, A Martín-Cardona, M Aicart-Ramos, J Tosca, MDM Martín-Rodríguez, C González-Muñoza, M Mañosa, E Leo-Carnerero, LJ Lamuela-Calvo, I Pérez-Martínez, L Bujanda, J Hinojosa, R Pajares, F Argüelles-Arias, JL Pérez-Calle, GE Rodríguez-González, J Guardiola, M Barreiro-de Acosta, JP Gisbert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading